Table 1 Demographics, comorbidities, and treatment of 29,851 children aged 2–17 years with actively treated asthma from a nationwide cohort
Overall (N = 29,851) | Ages 2–5 yrs (N = 10,105)a | Ages 6–11 yrs (N = 9895)a | Ages 12–17 yrs (N = 9851)a | |
|---|---|---|---|---|
Age | 9.0 (4.0, 13.0) | 3.0 (2.0, 4.0) | 9.0 (7.0, 10.0) | 15.0 (13.0, 16.0) |
Male | 17,646 (59%) | 6067 (60%) | 6362 (64%) | 5217 (53%) |
Specialist asthma care | 5864 (20%) | 1536 (15%) | 2295 (23%) | 2033 (21%) |
GINA 2020 step | ||||
Step 1 | N/A | N/A | 944 (9.5%) | 2921 (30%) |
Step 2 | N/A | 7895 (52%) | 1887 (19%) | 2881 (29%) |
Step 3 | N/A | 4736 (31%) | 3371 (34%) | 2797 (28%) |
Step 4 | N/A | 2497 (17%) | 3693 (37%) | 1042 (11%) |
Step 5 | N/A | N/A | N/A | 210 (2.1%) |
ICS dose | ||||
Below low | 7111 (22%) | 3883 (26%) | 1107 (11%) | 2121 (27%) |
Low | 9541 (32%) | 2601 (26%) | 2068 (21%) | 4872 (49%) |
Moderate | 8905 (30%) | 3368 (33%) | 3787 (38%) | 1750 (18%) |
High | 4958 (17%) | 1717 (17%) | 2933 (30%) | 308 (3.1%) |
Average daily exposed dose (mcg beclomethasone) | 247 (134, 401) | 201 (107, 329) | 267 (164, 406) | 280 (166, 468) |
Add-on therapies | ||||
Long-acting beta2-agonists | 6894 (23%) | 344 (3.4%) | 2125 (21%) | 4425 (45%) |
Long-acting antimuscarinics | 70 (0.2%) | 13 (0.1%) | 7 (< 0.1%) | 50 (0.5%) |
Leukotriene receptor antagonists | 6439 (22%) | 2248 (22%) | 2166 (22%) | 2025 (21%) |